Sawai Pharmaceutical’s $1.05 Billion Acquisition of the Generics Business of Upsher-Smith Laboratories

Debevoise & Plimpton LLP is advising Sawai Pharmaceutical Co. Ltd., a leading Japanese generic pharmaceuticals manufacturer, in its $1.05 billion acquisition of the generic pharmaceuticals business of Upsher-Smith Laboratories, Inc.

The transaction is expected to close near the end of June 2017.

Sawai focuses on the manufacturing and sales, export and import of generic pharmaceutical products and is the number one provider of generics to the Japanese market. Based in Minnesota, Upsher-Smith Laboratories, Inc., was founded in 1919 and is a growing, fully integrated pharmaceutical company. The acquisition will mark a major expansion of Sawai’s presence in the U.S. market.

The Debevoise team is led by partner Andrew L. Bab (Picture) and includes partners Gary M. Friedman, Sean Hecker, Elizabeth Pagel Serebransky, Scott B. Selinger, counsel Jacob W. Stahl, and associates Sean Heikkila, Michelle M. Hillenbrand, David P. Iozzi, Kamal Steven Nesfield, Molly D. Quinn, David R. Rock, Michael Ronca, Tsukasa Tahara, Lale Uner and Caitlin Wilcox.


Involved fees earner: Andrew Bab – Debevoise & Plimpton; David Iozzi – Debevoise & Plimpton; Molly Quinn – Debevoise & Plimpton; Michael Ronca – Debevoise & Plimpton; Tsukasa Tahara – Debevoise & Plimpton; Gary Friedman – Debevoise & Plimpton; David Rock – Debevoise & Plimpton; Sean Hecker – Debevoise & Plimpton; Sean Heikkila – Debevoise & Plimpton; Elizabeth Pagel Serebransky – Debevoise & Plimpton; Lale Uner – Debevoise & Plimpton; Scott Selinger – Debevoise & Plimpton; Kamal Nesfield – Debevoise & Plimpton; Jacob W. Stahl – Debevoise & Plimpton; Michelle Hillenbrand – Debevoise & Plimpton; Caitlin Wilcox – Debevoise & Plimpton;

Law Firms: Debevoise & Plimpton;

Clients: Sawai Pharmaceutical;



Author: Ambrogio Visconti